The Evolution of Risk Assessment in Pulmonary Arterial Hypertension
By: Sandhya Murthy and Raymond Benza
References
- Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med. 2004 Oct 14; 351(16): 1655–65. doi: 10.1056/NEJMra035488.
- Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987 Aug; 107(2): 216–23. doi: 10.7326/0003-4819-107-2-216.
- D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Int Med. 1991 Sep 1; 115(5): 343–9. doi: 10.7326/0003-4819-115-5-343.
- Barst R, Rubin L, Long W, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996 Feb 1; 334(5): 296–301. doi: 10.1056/NEJM199602013340504.
- Galié N, Humbert M, Vachiery J, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015 Oct; 46(4): 903–75. doi: 10.1183/13993003.01032-2015.
- Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010 Jul 13; 122(2): 164–72. doi: 10.1161/CIRCULATIONAHA.109.898122.
- Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010 Feb; 137(2): 376–87. doi: 10.1378/chest.09-1140.
- Umar S, Rabinovitch M, Eghbali M. Estrogen paradox in pulmonary hypertension: current controversies and future perspectives. Am J Respir Crit Care Med. 2012 Jul 15; 186(2): 125–31. doi: 10.1164/rccm.201201-0058PP.
- Chen
X,
Austin
ED,
Talati
M, et al. Oestrogen
inhibition reverses pulmonary arterial hypertension and associated metabolic
defects. Eur Respir J. 2017
Aug
3; 50(2):
1602337 . doi: 10.1183/13993003.02337-2016. - Paulin R, Michelakis ED. The Estrogen Puzzle in Pulmonary Arterial Hypertension. Circulation. 2012 Aug 28; 126(9): 1016–9. doi: 10.1161/CIRCULATIONAHA.112.126474.
- Umar S, Iorga A, Matori H, et al. Estrogen rescues preexisting severe pulmonary hypertension in rats. Am J Respir Crit Care Med. 2011 Sep 15; 184(6): 715–23. doi: 10.1164/rccm.201101-0078OC.
- Ventetuolo CE, Praestgaard A, Palevsky HI, Klinger JR, Halpern SD, Kawut SM. Sex and haemodynamics in pulmonary arterial hypertension. Eur Respir J. 2014 Feb; 43(2): 523–30. doi: 10.1183/09031936.00027613.
- Shapiro S, Traiger GL, Turner M, et al. Sex differences in the diagnosis, treatment, and outcome of patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Chest. 2012 Feb; 141(2): 363–73. doi: 10.1378/chest.10-3114.
- Karnes JH, Wiener HW, Schwantes-An T-H, et al. Genetic Admixture and Survival in Diverse Populations with Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2020 Jun 1; 201(11): 1407–1415. doi: 10.1164/rccm.201907-1447OC.
- Davis KK, Lilienfeld DE, Doyle RL. Increased mortality in African Americans with idiopathic pulmonary arterial hypertension. J Natl Med Assoc. 2008 Jan; 100(1): 69–72. doi: 10.1016/s0027-9684(15)31177-9.
- Chung L, Liu J, Parsons L, et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest. 2010 Dec; 138(6): 1383–94. doi: 10.1378/chest.10-0260.
- Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2004 Jun 16; 43(12 Suppl S): 40S–47S. doi: 10.1016/j.jacc.2004.02.032.
- Taichman DB, McGoon MD, Harhay MO, et al. Wide variation in Clinicians Assessment of New York Heart Association/World Health Organization Functional Class in Patients with Pulmonary Arterial Hypertension. May Clin Proc. 2009; 84(7): 586–592. doi: 10.4065/84.7.586.
- Lewis
RA,
Armstrong
I,
Bergbaum
C, et al.
EmPHasis-10 health-related quality of life score predicts
outcomes in patients with idiopathic and connective tissue disase-associated
pulmonary arterial hypertension: results from a UK multicenter
study. Eur Respir J. 2021;
57(2):
211124 . doi: 10.1183/13993003.00124-2020. - Macchia A, Marchioli R, Marfisi R, et al. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J. 2007 Jun; 153(6): 1037–47. doi: 10.1016/j.ahj.2007.02.037.
- Farber HW, Miller DP, McGoon MD, Frost AE, Benton WW, Benza RL. Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance. J Heart Lung Trans. 2015 Mar; 34(3): 362–8. doi: 10.1016/j.healun.2014.08.020.
- Wensel R, Opitz CF, Anker SD, et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation. 2002 Jul 16; 106(3): 319–24. doi: 10.1161/01.cir.0000022687.18568.2a.
- Shah SJ, Thenappan T, Rich S, Sur J, Archer SL, Gomberg-Maitland M. Value of exercise treadmill testing in the risk stratification of patients with pulmonary hypertension. Circ Heart Fail. 2009 Jul; 2(4): 278–86. doi: 10.1161/CIRCHEARTFAILURE.108.807826.
- Fu S, Ping P, Zhu Q, Ye P, Luo L. Brain Natriuretic Peptide and Its Biochemical, Analytical, and Clinical Issues in Heart Failure: A Narrative Review. Front Physiol. 2018 Jun 5; 9: 692. doi: 10.3389/fphys.2018.00692.
- Chin KM, Channick RN, Kim NH, Rubin LJ. Central venous blood oxygen saturation monitoring in patients with chronic pulmonary arterial hypertension treated with continuous IV epoprostenol: correlation with measurements of hemodynamics and plasma brain natriuretic peptide levels. Chest. 2007 Sep; 132(3): 786–92. doi: 10.1378/chest.07-0694.
- Williams MH, Handler CE, Akram R, et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J. 2006 Jun; 27(12): 1485–94. doi: 10.1093/eurheartj/ehi891.
- Mauritz G, Rizopoulos D, Groepenhoff H, et al. Usefulness of serial N-terminal pro-B-type natriuretic peptide measurements for determining prognosis in patients with pulmonary arterial hypertension. Am J Cardiol. 2011 Dec 1; 108(11): 1645–50. doi: 10.1016/j.amjcard.2011.07.025.
- Simpson CE, Damico RL, Hassoun PM, et al. Noninvasive Prognostic Biomarkers for Left-Sided Heart Failure as Predictors of Survival in Pulmonary Arterial Hypertension. Chest. 2020 Jun; 157(6): 1606–16. doi: 10.1016/j.chest.2019.12.037.
- Chakinala MM, Coyne DW, Benza RL, et al. Impact of declining renal function on outcomes in pulmonary arterial hypertension: A REVEAL registry analysis. J Heart Lung Transplant. 2018 Jun; 37(6): 696–705. doi: 10.1016/j.healun.2017.10.028.
- Quarck R, Nawrot T, Meyns B, et al. C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. J Am Coll Cardiol. 2009 Apr 7; 53(14): 1211–8. doi: 10.1016/j.jacc.2008.12.038.
- Lannan KL, Phipps RP, White RJ. Thrombosis, platelets, microparticles and PAH: more than a clot. Drug Discov Today. 2014 Aug; 19(8): 1230–5. doi: 10.1016/j.drudis.2014.04.001.
- Samokhin AO, Hsu S, Yu PB, et al. Circulating NEDD9 is increased in pulmonary arterial hypertension: A multicenter, retrospective analysis. J Heart Lung Transplant. 2020 Apr; 39(4): 289–299. doi: 10.1016/j.healun.2019.12.002.
- Raymond RJ, Hinderliter AL, Willis PW, et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol. 2002 Apr 3; 39(7): 1214–9. doi: 10.1016/s0735-1097(02)01744-8.
- Austin C, Alassas K, Burger C, et al. Echocardiographic assessment of estimated right atrial pressure and size predicts mortality in pulmonary arterial hypertension. Chest. 2015 Jan; 147(1): 198–208. doi: 10.1378/chest.13-3035.
- Forfia PR, Fisher MR, Mathai SC, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med. 2006 Nov 1; 174(9): 1034–41. doi: 10.1164/rccm.200604-547OC.
- Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010 Jul; 23(7): 685–713; quiz 786–8. doi: 10.1016/j.echo.2010.05.010.
- D’Alto M, Badagliacca R, Argiento P, et al. Risk Reduction and Right Heart Reverse Remodeling by Upfront Triple Combination Therapy in Pulmonary Arterial Hypertension. Chest. 2020 Feb; 157(2): 376–83. doi: 10.1016/j.chest.2019.09.009.
- Boxt LM, Katz J, Kolb T, Czegledy FP, Barst RJ. Direct quantitation of right and left ventricular volumes with nuclear magnetic resonance imaging in patients with primary pulmonary hypertension. J Am Coll Cardiol. 1992 Jun; 19(7): 1508–15. doi: 10.1016/0735-1097(92)90611-p.
- Roeleveld RJ, Marcus JT, Boonstra A, et al. A comparison of noninvasive MRI-base methods of estimating pulmonary artery pressure in pulmonary hypertension. J Magn Reson Imaging. 2005 Jul; 22(1): 67–72. doi: 10.1002/jmri.20338.
- Beerbaum P, Körperich H, Barth P, Esdorn H, Gieseke J, Meyer H. Noninvasive quantification of left-to-right shunt in pediatric patients: phase-contrast cine magnetic resonance imaging compared with invasive oximetry. Circulation. 2001 May 22; 103(20): 2476–82. doi: 10.1161/01.cir.103.20.2476.
- Baggen VJ, Leiner T, Post MC, et al. Cardiac magnetic resonance findings predicting mortality in patients with pulmonary arterial hypertension: a systematic review and meta-analysis. Eur Radiol. 2016 Nov; 26(11): 3771–80. doi: 10.1007/s00330-016-4217-6.
- Sieren
MM,
Berlin
C,
Oechtering
TH, et al.
Comparison of 4D Flow MRI to 2D Flow MRI in the pulmonary
arteries in healthy volunteers and patients with pulmonary
hypertension. PLoS One. 2019
Oct
24; 14(10):
e0224121 . doi: 10.1371/journal.pone.0224121. - Kelly RP, Ting CT, Yang TM, et al. Effective arterial elastance as index of arterial vascular load in humans. Circulation. 1992 Aug; 86(2): 513–21. doi: 10.1161/01.cir.86.2.513.
- Sunagawa K, Maughan WL, Sagawa K. Optimal arterial resistance for the maximal stroke work studied in isolated canine left ventricle. Circ Res. 1985 Apr; 56(4): 586–95. doi: 10.1161/01.res.56.4.586.
- Tello
K,
Dalmer
A,
Axmann
J, et al. Reserve of
Right Ventricular-Arterial Coupling in the Setting of Chronic
Overload. Circ Heart Fail.
2019
Jan; 12(1):
e005512 . doi: 10.1161/CIRCHEARTFAILURE.118.005512. - Noordegraaf AV, Channick R, Cottreel E, et al. Results from the REPAIR study final analysis: Effects of macitentan on right ventricular (RV) remodeling in pulmonary arterial hypertension (PAH). J Heart Lung Trans. 2020 Apr; 39(4): S16–17. doi: 10.1016/j.healun.2020.01.1140.
- Scott
J,
Lohmueller
L,
Kraisangka
J,
Kanwar
M,
Benza
R. Abstract 1174:
Hemodynamic parameters in predicting survival in pulmonary arterial
hypertension. Presented at: CHEST Annual Meeting
2019;
2019 Oct 19–23 ; New Orleans, LA. - Sun X, Hansen JE, Oudiz RJ, Wasserman K. Pulmonary function in primary pulmonary hypertension. J Am Coll Cardiol. 2003 Mar 19; 41(6): 1028–35. doi: 10.1016/s0735-1097(02)02964-9.
- Chandra S, Shah SJ, Thenappan T, Archer SL, Rich S, Gomberg-Maitland M. Carbon monoxide diffusing capacity and mortality in pulmonary arterial hypertension. J Heart Lung Transplant. 2010 Feb; 29(2): 181–7. doi: 10.1016/j.healun.2009.07.005.
- Benza RL, Gomberg-Maitland M, Miller DP, et al. The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest. 2012 Feb; 141(2): 354–362. doi: 10.1378/chest.11-0676.
- Weatherald J, Huertas A, Boucly A, et al. Association between BMI and obesity with survival in pulmonary arterial hypertension. Chest. 2018 Oct 1; 154(4): P872–881. doi: 10.1016/j.chest.2018.05.006.
- Aldred MA, Vijayakrishnan J, James V, et al. BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension. Hum Mutat. 2006 Feb; 27(2): 212–3. doi: 10.1002/humu.9398.
- Ma L, Chung WK. The genetic basis of pulmonary arterial hypertension. Hum Genet. 2014 May; 133(5): 471–9. doi: 10.1007/s00439-014-1419-3.
- Evans JDW, Girerd B, Montani D, et al. BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. Lancet Respir Med. 2016 Feb; 4(2): 129–37. doi: 10.1016/S2213-2600(15)00544-5.
- Benza RL, Gomberg-Maitland M, Demarco T, et al. Endothelin-1 Pathway Polymorphisms and Outcomes in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2015 Dec 1; 192(11): 1345–54. doi: 10.1164/rccm.201501-0196OC.
- Rhodes CJ, Batai K, Bleda M, et al. Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. Lancet Respir Med. 2019 Mar; 7(3): 227–238. doi: 10.1016/S2213-2600(18)30409-0.
- Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006 May 1; 173(9): 1023–30. doi: 10.1164/rccm.200510-1668OC.
- Benza RL, Elliott CG, Farber HW, et al. Updated risk score calculator for pulmonary arterial hypertension patients. J Heart Lung Trans. 2017 Apr; 36(4): S19. doi: 10.1016/j.healun.2017.01.038.
- Benza RL, Kanwar MK, Raina A, et al. Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension. Chest. 2021 Jan; 159(1): 337–346. doi: 10.1016/j.chest.2020.08.2069.
- Benza RL, Gomberg-Maitland M, Elliott CG, et al. Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies. Chest. 2019 Aug; 156(2): 323–337. doi: 10.1016/j.chest.2019.02.004.
DOI: https://doi.org/10.14797/LRPR7655 | Journal eISSN: 1947-6108
Language: English
Page range: 134 - 144
Accepted on: Nov 18, 2020
Published on: Jul 1, 2021
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services
Keywords:
© 2021 Sandhya Murthy, Raymond Benza, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.